Cost-Effectiveness Analysis for Public Health Practice: 1-2-3 Pap Intervention Example
Objective – To describe how a cost analysis (CA) and a cost-effectiveness analysis (CEA) can provide objective measures of program cost and expansion for public health program administration.
Methods – Using cost and efficacy data from the Rural Cancer Prevention Center (a CDC-funded Prevention Research Center), a CA was done of a hypothetical program to expand the 1-2-3 Pap intervention in rural Kentucky. We also conducted a CEA to estimate the cost per completed three-dose vaccine series.
Results –If 1-2-3 Pap were expanded to the Kentucky River Area Development Region, the number of young women covered by the intervention would increase by a thousand and the number of women completing the vaccine series would be four times as many. The intervention cost per completed three-dose series was $536.
Implications –Our study is the first to our knowledge to quantify the costs of an intervention to improve 3-dose HPV vaccine coverage. HPV vaccine cost-effectiveness models suggested that programs to improve HPV vaccine coverage can be cost-effective, even if these programs incur additional costs. Our cost estimates can inform future analyses of strategies to increase HPV vaccine coverage in the US.
Learning Areas:Administration, management, leadership
Chronic disease management and prevention
Protection of the public in relation to communicable diseases including prevention or control
Public health administration or related administration
Public health or related organizational policy, standards, or other guidelines
Define cost analysis and cost-effectiveness analysis for public health practice; Describe the value of a cost analysis and a cost-effectiveness analysis for public health interventions, such as the 1-2-3 Pap intervention; Discuss how routine implementation of a cost analysis and/or a cost-effectiveness analysis improve equity in access, quality, and outcomes of public health interventions
Keyword(s): Economic Analysis, Chronic Disease Prevention
Qualified on the content I am responsible for because: I am a Prevention Effectiveness Fellow who conceptualized, designed, and led this study.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.